Drug Diversion Prevention The Mayo Clinic Experience

Similar documents
Patient Safety. Road Map to Controlled Substance Diversion Prevention

Data Analytics In Healthcare Diversion Prevention, Detection and Response Quality Improvement

Drug Diversion Exercise. New Jersey Department of Health Pilot Project-Safe Injection Practices January/February 2016

Understanding Diversion in the Pharmacy Kimberly S. New JD BSN RN

Pharmaceutical Diversion Prevention, Detection and Incident Response

Drug Diversion Tabletop Exercise for Ambulatory Surgery Centers (ASCs) Facilitator Guide with Scenarios

Effectively Managing and Monitoring Controlled Substances in Research

Topics 5/16/2017. Effectively Managing and Monitoring Controlled Substances in Research

A Million Little Pieces: Developing a Controlled Substance Diversion Program. Tanya Y. Barnhart, PharmD, BCPS

Not if, but When: Drug Diversion in Hospitals. Christopher Fortier, PharmD, FASHP Chief Pharmacy Officer Massachusetts General Hospital Boston, MA

Medication Management and Diversion Control

Understanding Diversion

Development of a Road Map to Controlled Substance Diversion Prevention

Management of Controlled Substances Ambulatory Care with Electronic Key Control Cabinet

Definitions: In this chapter, unless the context or subject matter otherwise requires:

Management of Controlled Substance

AHLA. T. Diversion of Controlled Substance in Health Care Setting

10/4/12. Controlled Substances Dispensing Issues and Solutions. Objectives. Financial Disclosure

Medication Diversion and Prescription Drug Abuse in the Long Term Care Setting. Objectives

NEW JERSEY. Downloaded January 2011

Prepared for the Foundation of the American College of Healthcare Executives Session 101AB Not If, but When: Drug Diversion in Hospitals

3/9/2010. Objectives. Pharmacist Role in Medication Safety and Regulatory Compliance

PARAGOULD DOCTORS CLINIC PRIVACY NOTICE

Medication Safety Action Bundle Adverse Drug Events (ADE) All High-Risk Medication Safety

A powerful medication management tool for the new healthcare environment

Policies Approved by the 2017 ASHP House of Delegates

Incident Planning Guide: Infectious Disease

CareFusion Overview Scott Bostick SVP/GM Pyxis Dispensing Technologies

PACKAGING, STORAGE, INFECTION CONTROL AND ACCOUNTABILITY (Lesson Title) OBJECTIVES THE STUDENT WILL BE ABLE TO:

Implementation of Remote Management of Compounded Sterile Products through the use of a Telepharmacy System

Compliance Made Simple: 24/7/365

SECTION HOSPITALS: OTHER HEALTH FACILITIES

Optimizing Medication Safety in Maryland Assisted Living Facilities. Panel Discussion Moderated by: Nicole Brandt, PharmD

Galveston Area Ambulance Authority Controlled Substance Guidelines

Transitions of Care. Objectives 1/6/2016. Roman Digilio, PharmD PGY1 Resident West Kendall Baptist Hospital. The author has nothing to disclose.

California Pharmacy Law Update 2018

It s every OR manager s nightmare a drug diversion that hits the local

Drug Distribution Services for Long Term Care Facilities. Susan L. Lakey, PharmD 1/11/06

PRESCRIBING IN NEVADA

COMPLIANCE WITH THIS PUBLICATION IS MANDATORY THIS DOCUMENT IS AVAILABLE AT THE FOLLOWING URL:

NATIONAL ASSOCIATION FOR STATE CONTROLLED SUBSTANCES AUTHORITIES (NASCSA) MODEL PRESCRIPTION MONITORING PROGRAM (PMP) ACT (2016) COMMENT

Notice of HIPAA Privacy Practices Updates

Scope of the Problem. Leadership Engagement. Leadership Engagement. Risk of Harm to Patients. Risk of Harm to Patients 6/13/2016

POSITION STATEMENT. - desires to protect the public from students who are chemically impaired.

Audience Poll Questions

HIPAA Notice of Privacy Practices DFD Russell Medical Center Effective April 14, 2003 Updated April 10, 2013

SHORTAGES IN MENTAL HEALTH COVERAGE 10/31/2016. CPE Information and Disclosures. Learning Objectives. CPE Information

NEW MEXICO PRACTITIONER S MANUAL

The Benefits of Standardization: Anesthesia Cart Standardization in 62 Operating Rooms Over 5 Surgical Sites

NOTICE OF PRIVACY PRACTICES FOR MAYO CLINIC ARIZONA

JCI 6 th ed. Hospital Standards Review: Patient-Centered Standards

Regulation of Hospital Pharmacy. Board of Pharmacy Authority. The New & Proposed Changes to the Hospital Licensing Rules. Conflict of Interests

WAKE FOREST BAPTIST HEALTH NOTICE OF PRIVACY PRACTICES

DC Board of Pharmacy and Pharmaceutical Control Update

Pharmaceutical Services Instructor s Guide CFR , (a)(b)(1) F425

NOTICE OF PRIVACY PRACTICES

Stephen C. Joseph, M.D., M.P.H.

MINNESOTA BOARD OF PHARMACY

CHAPTER 18 CONTROLLED SUBSTANCES

University of Michigan Health System. Final Report

Laguna Honda Hospital and Rehabilitation Center. Security Management Plan

Evidence-Based Practices to Optimize Prescriber Use of PDMPs

a remote pharmacy is not necessarily intended to provide permanent??? how do we make it so that it may be only for limited duration.

2017 ASHP Proposed Policies: To Approve or Not to Approve, That is the Question. Disclosures. Learning Objectives 3/16/2017

Prescription Monitoring Program State Profiles - Illinois

C. Physician s orders for medication, treatment, care and diet shall be reviewed and reordered no less frequently than every two (2) months.

(b) Service consultation. The facility must employ or obtain the services of a licensed pharmacist who-

DIVISION OF MENTAL HEALTH AND ADDICTION SERVICES ADMINISTRATIVE BULLETIN A.B. 5:04B

CHAPTER 117. EMERGENCY SERVICES GENERAL PROVISIONS EMERGENCY SERVICES PLANNING ORGANIZATIONS

Department of Defense INSTRUCTION

PHARMACY RULES COMMITTEE of the PHARMACY EXAMINING BOARD

SAC (Senate Appropriations Committee) PROGRAM PRESIDENT HAC (House Appropriations Committee) DOJ Byrne Memorial Justice Assistance Grants Coverdell

Mental Health. Notice of Privacy Practices

Using Electronic Health Records for Antibiotic Stewardship

38 May June 2014 OI

Chapter 13 Section 1

Taranaki District Health Board

HEALTH EMERGENCY MANAGEMENT CAPACITY

Licensed Pharmacy Technicians Scope of Practice

NOTICE OF PRIVACY PRACTICES UNIVERSITY OF CALIFORNIA IRVINE HEALTHSYSTEM

Automation and Information Technology

PREPARATION AND ADMINISTRATION

Legal Implications Recommended Practices

NURSE MONITORING PROGRAM HANDBOOK

CPhT Program Recognition Attestation Form

San Francisco General Hospital INFECTION CONTROL

Notice of Health Information Privacy Practices Acknowledgement

SAC (Senate Appropriations Committee) PROGRAM PRESIDENT HAC (House Appropriations Committee) DOJ Byrne Memorial Justice Assistance Grants Coverdell

SUMMARY OF NOTICE OF PRIVACY PRACTICES

Note: 44 NSMHS criteria unmatched

PHARMACEUTICALS AND MEDICATIONS

Optimizing pharmaceutical care via Health Information Technology:

REVISED FIP BASEL STATEMENTS ON THE FUTURE OF HOSPITAL PHARMACY

DISEASE SURVEILLANCE AND REPORTING REGULATION

PEDIATRIC HEALTH ASSOCIATES HIPAA NOTICE OF PRIVACY PRACTICES

Introduction. Singapore and its Quality and Patient Safety Position. Singapore 2004: Top 5 Key Risk Factors. High Body Mass

K-TRACS: Review of Program Data and a Qualitative Assessment Study

Department of Human Services PROPOSED FY 2019 BUDGET HIGHLIGHTS. County Board Work Session February 28, 2018

NOTICE OF PRIVACY PRACTICES

New Jersey State Department of Health and Senior Services Healthcare-Associated Infections Plan 2010

Transcription:

Drug Diversion Prevention The Mayo Clinic Experience Kevin R. Dillon, Pharm.D., MPH Director of Pharmacy Services Mayo Clinic Health Care Compliance Association Upper Midwest - Regional Annual Conference September 19 th, 2014 In order to be trusted.we must be safe. John H. Noseworthy, M.D., President & CEO, Mayo Clinic 1 Conflict of Interest Declaration No conflicts to disclose 2 1

Learning Objectives Learning Objectives 1. Describe the key components of the Mayo Clinic Drug Diversion & Prevention Program. 2. Describe the Mayo Clinic Elements of Best Practice: Drug Diversion Prevention and Detection 3. Describe the role of law enforcement in healthcare drug diversion. 4. Understand the affordability of a Drug Diversion Prevention and Detection Program. 3007033-33 The Mayo Clinic Journey. High profile fentanyl tampering (2008) Catalyst for Change Drug Diversion & Prevention Task Force Charge: Comprehensively review the existing controlled substance system to identify opportunities for improvement Scope: Hospital Inpatient, Hospital-based OP, Clinic OP Multidisciplinary Approach to Work: Failure Mode Effects Analysis Surveillance Program Investigation & Response 4 2

Failure Mode Effects Analysis Multidisciplinary Workgroup Mapped current CS medication use processes (prescribing, procurement, storage, preparing & dispensing, administration, monitoring) Identified diversion risk points and potential causes Identified process changes that will minimize risk points 5 Risk Point Categories 1. Unobserved Single Individual Access to Controlled Substances Potential for diversion when same person performs the task; minimal or busy staffing in the area; and minimal double checks in place Current standard of practice in most areas Examples: Nurse / Anesthesiologist / Other Practitioner retrieves CS from Pyxis machine and administers to patient Pharmacy Technician delivers CS from Pharmacy to patient care area 2. Unattended Product During Medication Use Processes Potential for diversion when the chain of custody is broken Examples: CS located unattended waiting RPh verification CS located in a procedural room waiting administration CS located on a Pharmacy delivery cart Technician returning CS from floors to CII Safe Medications left in procedural drawers 6 3

Risk Point Categories 3. Deviation from Policy / Procedures Potential for diversion when process steps are skipped or minimized due to reasons of efficiency / convenience / necessity Employee performance Examples: Unwitnessed witnessing of CS waste Sharing of Pyxis system passwords 4. Lack of Audit Process / Known Deterrent Any time there is a known lack of an audit process or deterrent there is potential for deviant behavior Examples: Lack of integration between CS retrieval and administration documentation Presence / absence of camera Timeliness of surveillance audits and feedback 5. Other Process Assessments Patients Own Meds processes 123 potential process improvement changes identified 7 Mayo Clinic Medication Diversion Prevention Medication Diversion Prevention Coordinator Initial point of contact for all suspected diversions Coordinates the preliminary investigation Initiates and coordinates meetings with Drug Diversion Response Team (DDiRT) Participates in intervention Interfaces with law enforcement when needed Oversees diversion surveillance program and team members Maintains data base of cases Assures proper reporting to authorities before case closed 8 4

Mayo Clinic Medication Diversion Prevention Reporting Process Established Hot Line 24x7 pager Widely publicized Originally signage on Pyxis machines - removed Institutional compliance line Anonymous reporting if desired 9 Mayo Clinic Medication Diversion Prevention Surveillance Program Report generation & data analytics ADM and medical record data utilized 26 + reports (daily, weekly, monthly) - FMEA risk points Analytics tool (vendor, in-house) Moving towards centralization Waste collection & analysis CS waste returned to pharmacy in anesthesia areas, ED, GI Labs (expand to other areas?) Randomly assayed (Quantitative vs Qualitative) Strict reconciliation of records Audits Order vs removal vs administration vs pain scales Manual vs electronic Review of Paper CS Inventory & Disposition records Camera surveillance (High volume areas, For Cause surveillance) OP prescription monitoring 10 5

Mayo Clinic Medication Diversion Prevention Drug Diversion Response Team (DDiRT) A multidisciplinary team to provide expert consultation and direction regarding suspected medication diversion cases Meets within 24 hours includes applicable manager, HR partner, etc. Reviews and discusses available evidence to determine if potential diversion exists Recommends next steps (e.g. further monitoring, immediate intervention, employee interview, etc.) Internal / External reporting Ensures consistent, standardized approach 11 12 6

Mayo Clinic Medication Diversion Prevention Committee / Management Oversight Medication Diversion and Prevention Subcommittee x 2 Local (Rochester) Pharmacy & Therapeutics Committee - Medication Diversion and Prevention Subcommittee Multidisciplinary Enterprise Mayo Clinic Clinical Practice Committee - Medication Diversion and Prevention Subcommittee Multidisciplinary; Multiple sites; Enterprise based 13 Mayo Clinic Medication Diversion Prevention Elements of Best Practice (Late 2010) Developed by Pharmacy with consensus input from others Purpose to establish core structure & processes that would optimize the detection and minimize the occurrence of controlled substance diversion 77 elements. Ongoing review. Categorized as Tier 1 / Tier 2 Used as foundation for independent assessments across other sites Green-Yellow-Red stop light assessment grid to allow tracking of progress Expectation is ALL sites implement NEW! Elements of Best Practice Outpatient Pharmacy! 14 7

Elements of Best Practice Compliance 15 When / How to Involve Law Enforcement Often times confusing and even contentious issue Establish contact with local law enforcement before the need arises Be familiar with reporting requirements (local, state, federal) Significant Loss and any theft must be reported to DEA within one business day Boards of Nursing, Pharmacy, Medicine, etc Considerations: Law Enforcement brings different skills and tool kit Facilitates criminal prosecution case Loss of control 16 8

How can we afford it? Schaefer, Perz Mayo Clinic Proceedings article (see resources) Provides a unique & frightening look at the harm a drug-diverting healthcare worker can inflict Identified 6 US Outbreaks of drug diversion-related bloodstream infections from 2003-2013 2 outbreaks: gram neg bacteremia 34 patients 4 outbreaks: hepatitis C transmission 84 patients Collateral Damage 4 Hep C outbreaks = potential exposure of 30,000 patients Patient notifications, testing, anxiety Lawsuits! Impacted patients Reverse lawsuits Question becomes not How can we afford a program to prevent and detect drug diversion by HCW s? but instead How can we afford to not have such a program? 17 Summary / Lessons Learned Theft of controlled substances is common in the healthcare workplace. This is a journey.not a destination. Learn from each episode. Have a drug diversion detection and prevention program in place. Addiction & Diversion is a multi-victim crime. It s all about the details. Focus on high risk areas first (e.g. anesthesia, procedural areas, ED) but don t forget about the unusual areas (e.g. animal research, clinical laboratory). 18 9

Summary / Lessons Learned Robust surveillance is critical. If you look you will find it. If you don t find it you re probably not looking hard enough. All employees divert, even employees with no access to drugs Waste stream is under constant attack Educate and be transparent solicit the help of the 99.9% Requires strong, active multidisciplinary leadership Optimize technology Requires resources Don t recreate the wheel 19 Resources Minnesota Controlled Substance Diversion Prevention Coalition Coordinated by the Minnesota Department of Health and the Minnesota Hospital Association http://www.health.state.mn.us/patientsafety/drugdiversion/index.html Diversion of Drugs Within Health Care Facilities, a Multi-Victim Crime: Patterns of Diversion, Scope, Consequences, Detection and Prevention. KH Berge, KR Dillon, et al. Mayo Clinic Proceedings. July 2012; 87(7): 674-682. Outbreaks of Infections Associated With Drug Diversion by US Health Care Personnel. MK Schaefer, JF Perz. Mayo Clinic Proceedings. July 2014; 89(7):878-887. Bloodstream Infection Outbreaks Related to Opioid-Diverting Health Care Workers: A Cost-Benefit Analysis of Prevention and Detection Programs Editorial. KH Berge, WL Lanier. Mayo Clinic Proceedings. July 2014; 89(7):866-868. 20 10

Thank You! 21 11